DR. PAUL G. HARCH’S
Since 1986 Dr. Harch’s hyperbaric medicine practice has progressively expanded to include HBOT for off-label indications as well as the 13 “accepted” and five “non-accepted” Medicare/Medicaid indications (see discussion on HYPERBARIC OXYGEN THERAPY INDICATIONS). Currently, Dr. Harch performs consultations on any patient seeking HBOT for any indication, “accepted” or off-label. He provides second opinions, assesses patients with any type of central nervous system disorder, evaluates patients’ potential to rehabilitate with HBOT, and accepts patients regardless of their involvement in litigation. HBOT is delivered according to protocols developed by Dr. Harch since 1986 and individually customized to each patient’s condition. These protocols are the basis for nearly all off-label neurological HBOT in the United States today and many of the research trials. These protocols have been applied to over 50 different chronic neurological disorders across the broad categories of vascular, traumatic, ischemic/hypoxic, toxic, degenerative, convulsive (seizures), autoimmune, dementia, and pediatric. A particularly large experience has been generated in stroke, trauma, carbon monoxide, seizure, and pediatric brain disorders, especially CP. Since HBOT is a drug, proper dosing is necessary to avoid toxicity that has been identified by Dr. Harch’s research and clinical practice.
DR. PIERRE MAROIS M.D., F.R.C.P.(C)
He has been associated with cerebral palsy research projects at McGill University . In his career, he has had the opportunity to observe and to treat several thousand children with cerebral palsy and brain insults. He has expertise in this field and is a highly respected physician. He is responsible for the treatment of 1,500 children having the diagnosis of cerebral palsy, working with many rehabilitation teams in the province of Quebec. Dr. Marois has specific expertise in the oxygenation process, having been one of the leaders of a research team involved in oxygenation projects from 1998-2001 for which he received the inaugural Richard A. Neubauer award. He has put together in 1982 the first dorsal rhizotomy clinic in North America, for the treatment of cerebral palsy. He is actively involved in researches and in the development of techniques for the treatment of handicapped children. He initiated and participated in the three studies that were completed in Canada on Hyperbaric Oxygen Therapy and Cerebral palsy and has lectured in many international meetings on that subject.
DR. DAN ROSSIGNOL
DAN Rossignol, MD, FAAFP has special interest in Autism Spectrum Disorders, PANDAS, Cerebral Palsy, and related neurological and developmental disorders as well as medically complex children and adults. Dr. Rossignol received his Doctorate of Medicene at the Medical College of Virginia and comleted his residency in family medicine at the University of Virginia. He is currently a physician at ICDRC in Melbourne, FL. Coming from an academic background, Dr. Rossignol searched the medical literature looking for a solution after both of his children were diagonized with autism. Finding no obvious solution, he made it his mission to reach and publish in autism. In the last 5 years, he has published 8 papers as the lead author for a total of 14 papers on autism with 5 more to be published this year. He has also written 3 book chapters on autism. Dr. Rossignol received the prestigious Edgar End Memorial Award from the Undersea Hyperbaric Medical Society for his pioneering paper in hyperbaric research in autism.
DR. JAMES A. NEUBRANDER
Dr. James A. Neubrander is one of the most aggressive DAN doctors. Dr. Neubrander co-authored the 2004 landmark paper “Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.” which led to his pioneering use of methyl-B12 injections as discussed at the 2005 DAN conference in Boston. See “Methyl-B12: Myth, Masterpiece, Or Miracle?”
Dr. Neubrander incorporated hyperbaric therapy into his practice in 2005. He utilizes an unorthodox protocol of atmospheric pressure multiplied by the time spent at pressure multiplied by arterial oxygen generated by pressure multiplied by oxygen concentration. One of his most ingenious developments is a traditional HBOT assessment instrument and also a mHBOT assessment instrument. Both are utilized to determine HBOT efficacy in autistic children. Dr. Neubrander’s web page also features a huge collection of testimonial videos from parents that is really worth checking out.
J. MICHAEL USZLER
J. Michael Uszler, M.D. is the Medical Director of DrSpectScan.com and an Assistant Clinical Professor of Molecular and Medical Pharmacology at UCLA. As a board certified Nuclear Medicine physician he has 3 decades of academic and clinical experience in hospital-based care, including 8 years at UCLA-Harbor General Hospital, 20 years as Medical Director of Nuclear Medicine at Santa Monica Hospital, and now at Saint Johns Health Center in Santa Monica, as well as in private practice. For the last 20 years he has focused extensively on quantitative regional brain function imaging as part of Nuclear Medicine’s moving into metabolic and molecular function imaging. He is nationally recognized for his expertise of brain SPECT imaging of disorders such as Autistic Spectrum Disorders, Cerebral Palsy, ADD/ADHD, near-drowning, closed head trauma, toxic encephalopathy, stroke and dementia, and in using SPECT and PET brain function imaging to follow the effectiveness of various therapies of these conditions, particularly Hyperbaric Oxygen Therapy.